De Novo device
Comfort Marker 2.0
Medical Precision BV · Radiation Therapy Marking Device (QRN, Class II) · First FDA decision Dec 10, 2021, newest Mar 30, 2023Cancer radiation therapy
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
1
Naming "Comfort Marker 2.0"
MAUDE reports
0
Brand "Comfort Marker 2.0", since 2015
PubMed studies
3
Mentioning "Comfort Marker 2.0"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Comfort Marker 2.0
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Comfort Marker 2.0510(k)
K222112 · Decided Mar 30, 2023 · 255 days after receipt
Device type: Radiation Therapy Marking Device (QRN) · Radiology & Imaging
- Comfort Marker 2.0.New device typeDe Novo
DEN200041 · Decided Dec 10, 2021 · 536 days after receipt
Device type: Radiation Therapy Marking Device (QRN) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hyperbaric Oxygen Therapy for Chronic Radiation Induced Proctitis and EnteritisNational analysisReview closedCAG-00060R2Updated Nov 18, 2026
- Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT)Local determinationIn effectL35076Wellpoint FederalUpdated Jul 14, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40168Wellpoint FederalUpdated Jul 14, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40179CGS Administrators, LLCUpdated Apr 17, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40193WPS Insurance CorporationUpdated Mar 12, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40189Palmetto GBAUpdated Mar 11, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40176Noridian Healthcare Solutions, LLCUpdated Mar 10, 2026
- Intraoperative Radiation TherapyLocal determinationIn effectL37779Palmetto GBAUpdated Jul 23, 2021
Clinical trials
Device studies on ClinicalTrials.gov that name "Comfort Marker 2.0", any status and sponsor, newest update first.
- Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking DevicePivotal-lookingStatus unknown
Instituto Portugues de Oncologia, Francisco Gentil, PortoAcademic, hospital or other
NCT05371795 · 100 participants · Start Oct 18, 2021 · Primary completion Mar 11, 2022
Device: Comfort Marker 2.0; Lancets · For: Radiotherapy; Tattooing
Sites: Porto, Portugal
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Comfort Marker 2.0", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QRN
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Comfort Marker 2.0"[tiab]. The summary above synthesizes these.
- Clinical experience of a tattoo application device.
Brown E, Barry T, Mai T, et al. · Tech Innov Patient Support Radiat Oncol · 2024
- Radiation Therapy Skin Marking with Lancets Versus Electric Marking Pen (COMFORTATTOO)-6 Months Results on Cosmesis, Fading, and Patients' Satisfaction From a Randomized, Double-Blind Trial.
Pires AM, Carvalho L, Santos AC, et al. · Adv Radiat Oncol · 2024
- Radiotherapy skin marking with lancets versus electric marking pen - Comfort, satisfaction, effectiveness and cosmesis results from the randomized, double-blind COMFORTATTOO trial.
Pires AM, Carvalho L, Santos AC, et al. · Radiography (Lond) · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.